GL1X · GenesisL1 explorer

MolNFT v1 · #121486 · protein

Crystal structure of DR2231_E46A mutant in complex with dump and magnesium

5HX1: “Crystal structure of DR2231_E46A mutant in complex with dump and magnesium”. X-ray diffraction, 2 ligands (UMP, MG), 8 pockets (best druggability 0.74). MolNFT v1 #121486 on GenesisL1: 3D structure, binding sites and pockets in GL1X.

PDB
5HX1
Type
protein
Length
537 residues
Chains
4
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
DR2231
UniProt
Q9RS96
Ligands
UMP, MG
Pockets
8 · best druggability 0.74

Structure

x-ray diffraction · 3 distinct chains · 67% helix, 1% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BDR2231protein13863% helix, 1% strandQ9RS96
CDR2231protein13069% helix, 0% strandQ9RS96
DDR2231protein13168% helix, 0% strandQ9RS96

Ligands and binding sites

  • UMP · 2'-deoxyuridine 5'-monophosphate · ligand · 2 copies · chains A, C, B, D
  • MG · Magnesium ion · metal · 4 copies · chains A, B, C, D

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

8 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14780.740.8251UMP
24190.730.8347UMP
3790.370.7719empty
4730.370.7818empty
5610.370.7916empty

Interfaces

6 interfaces between chains.

  • A–C · 3010 Ų buried · 22 hydrogen bonds · protein-protein
  • B–D · 3005 Ų buried · 19 hydrogen bonds · protein-protein
  • A–B · 223 Ų buried · 5 hydrogen bonds · protein-protein
  • B–C · 155 Ų buried · 1 hydrogen bond · protein-protein
  • A–D · 134 Ų buried · 1 hydrogen bond · protein-protein

Compared structures

  • 5HX1 · Crystal structure of DR2231_E46A mutant in complex with dUMP and magnesium · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.